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Biomarkers in Epidemiology
Philippe Grandjean
A biomarker is a measurable event occurring in a biolog-
ical system, such as the human body. In environmental
epidemiology, a biomarker represents a subclinical and
reversible change; it is not a diagnostic test, but an
indicator that an early change has occurred that could
later lead to clinical disease. Although some biomarkers
may belong to more than one class, they are often
separated into biomarkers of exposure, biomarkers of
effect, and biomarkers of suceptibility. Biomarkers can
be used to classify and quantify environmental exposures
and their related effects, and many methods may be
applicable in toxicological experiments as well as in
epidemiology. Accordingly, biomarker epidemiology is
undergoing rapid development and expansion and is
becoming one of the most promising areas of environ-
mental research. Although expanded applications should
be encouraged, many biomarkers are poorly character-
ized, and attention should be paid to defining their
properties in detail.
Indexing Terms: environmental toxicology/epidemiology
The term biomarker has entered the epidemiological
and environmental vocabulary as a short form for
biological marker or biochemical marker. The first
European conference on biomarkers in environmental
toxicology was held in 1993 (1). Biomarker refers to a
measurable event occurring in a biological system,
such as the human body (2,3). This event is then
interpreted as a reflection of a more general state of the
organism or the life expectancy of an individual. In
addition to biological marker (2, 4), other terms have
occasionally been used with the same meaning. For
example, a recent publication entitled “Biomarkers in
ecotoxicology” (5) was referred to as “Bioindicators in
ecotoxicology” in the table of contents. For the sake of
uniformity, biomarker would seem to be the most
appropriate term.
To be useful in epidemiology, the measurable event
in the human body should represent a subclinical
change only. A biomarker is not a diagnostic test, but
an indicator that an early change has occurred that
could later lead to clinical disease. Especially for use in
preventive medicine, the change should be completely
reversible. To trigger appropriate action, a biomarker
finding should also be amenable to interpretation with
regard to causal factors in the environment, and poten-
tial preventive efforts should be realizable, at least in
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principle. Also, from an ethical viewpoint (6), the prac-
tical use of the biomarker should be regarded as
acceptable.
A biomarker reflects an event or a sequence of events
that occur somewhere in the causal chain between an
exposure to a hazardous factor and a related adverse
effect. Theoretically, these events can be separated into
those indicating “internal dose,” “effective dose,” etc.,
but some of these terms themselves are difficult to
define, and a detailed classification of biomarkers may
not necessarily add to the understanding of their prop-
erties. Nonetheless, three specific types of biomarkers
are usually identified (Fig. 1) (2, 3). Although some
biomarkers may belong to more than one class, they
are often separated into biomarkers of exposure,
biomarkers of effect, and biomarkers of suceptibility.
As illustrated by papers presented at the Biomarker
Conference in 1993 (1) and the present proceedings, all
three types of biomarkers are extremely useful in
epidemiological studies.
Exposure Biomarkers
An exposure biomarker may be a xenobiotic com-
pound or metabolite within the body, an interactive
product between the compound (or metabolite) and an
endogenous component, or another event related to the
exposure (2, 3). Most commonly, biomarkers of expo-
sures to stable compounds are assessed by measuring
their concentrations in appropriate samples, such as
blood, serum, or urine. The concentration of a volatile
chemical may be assessed in exhaled breath. If the
compound is metabolized in the body, one or more
metabolites may be determined, e.g., in a urine sample.
Especially with mutagenic chemicals, some promising
analytical developments have been realized (7). Ad-
ducts formed with DNA can now be detected in white
Fig. 1. Three major types of biomarkers have been recognized, but
overlapping may occur.
CLINICAL CHEMISTRY, Vol. 41, No. 12, 1995 1801
blood cells or tissue biopsies, and specific DNA frag-
ments may be identified in the urine. Hemoglobin
adducts may be a feasible biomarker, but no repair
occurs, and they may not accurately reflect the effects
in the target organ. On the other hand, hemoglobin
adducts indicate the integrated event during the
4-month lifetime of red blood cells. One may speculate
that adducts with other proteins, such as collagen,
could become useful as indicators of exposures during
much longer exposure periods. Although such adducts
are the result of a biological effect, they are usually
considered exposure biomarkers.
Temporal aspects are important for all exposure
biomarkers, not only for adducts. Evidence must be
obtained to show the extent to which short-term vari-
ations in the exposure affect distribution, retention,
and interaction with the target molecules. Sometimes,
such toxicokinetic evidence is used to classify a bio-
marker as an indicator of (total) absorbed dose or an
indicator of effective dose (i.e., the amount that has
reached the target tissue). Although few biomarkers
have been fully characterized in this regard, extended
application in epidemiology should be encouraged to
assist in the elucidation of these aspects.
Effect Biomarkers
A marker of effect may be an endogenous component,
or a measure of the functional capacity, or some other
indicator of the state or balance of the body or organ
system, as affected by the exposure. Such effect mark-
ers are generally preclinical indicators of abnormali-
ties. These biomarkers may be specific or nonspecific.
The specific biomarkers are useful because they indi-
cate a biological effect of a particular exposure, thus
providing evidence that can potentially be used for
preventive purposes. The nonspecific biomarkers do
not point to an individual cause of the effect; rather,
they indicate the total, integrated effect that could be
due to a mixed exposure.
As discussed, e.g., by Harris et al. (7), biomarkers
may be crucial for the evaluation of genotoxic effects of
environmental chemicals. In particular, methods used
for assessing genotoxicity in humans may also be
applied in animal experiments in which they can be
compared with data on target tissues that cannot be
examined in human subjects. Such studies of causal
chains may provide new insight into disease pathogen-
esis. In this way, biomarkers constitute a common
ground to be explored jointly by toxicologists and epi-
demiologists. Not surprisingly, this research area has
attracted much attention, although predominantly in
relation to cancer.
A recent publication from the International Program
on Chemical Safety (IPCS) (8) reviews the applications
of biomarkers, including those that indicate effects on
different organ systems. Although very useful in this
regard, it includes the following adverse health effects
as examples of biomarkers: liver cell necrosis, de-
creased pulmonary function, low birth weight, and
mental retardation. Thus, according to IPCS, certain
medical diagnoses could be used as biomarkers. How-
ever, this application of the term may lead to confusion.
The medical diagnoses mentioned should instead be
referred to as sentinel events (9). A biomarker in the
stricter sense of the word does not represent the
diagnosis or the sentinel event itself, but rather reflects
a risk that such pathology could develop at a later
stage.
A biomarker therefore is like a symbol, which has a
depth of meaning (regarding risk) greater than that
represented by its immediate appearance (the change
per se). Epidemiological evidence is of key importance
to document the interpretation of the biomarker with
regard to such risk.
Susceptibility Biomarkers
A marker of susceptibility, whether inherited or
induced, is an indicator that the individual is particu-
larly sensitive to the effect of a xenobiotic or to the
effects of a group of such compounds. Most attention
has focused on heterogeneities of enzymes involved in
the metabolism of xenobiotics (7), although other non-
genetic factors are likely to be at least as important.
Hypersusceptibility is a well-known but insufficiently
explored phenomenon in epidemiology. It may be due
to an inherited trait, to the constitution of the individ-
ual, or to environmental factors (10).
A particularly promising aspect relates to hypersus-
ceptibility caused by depletion of the reserve capacity.
The human body seems to possess a certain capacity to
withstand potentially adverse effects of chemical expo-
sures. However, an individual’s resistance toward
chemical toxicity may be decreased by a preexisting
disease or by additional environmental exposures, in-
cluding those associated with diet and life-style (10). A
previous exposure may not necessarily have resulted in
recognized toxicity, but could conceivably have caused
a weakening of body defenses, i.e., a decrease in the
reserve capacity. Biomarkers of reserve capacity could
therefore reflect both effect and susceptibility, e.g.,
related to the immune system, the hemopoietic system,
or the kidneys. Such biomarkers would be particularly
promising for epidemiological studies.
Applications in Epidemiology
As indicated above, biomarkers have important ap-
plications in epidemiology as well as in preventive
medicine and environmental health. A major aim of
epidemiological studies is to identify and evaluate risk
factors associated with disease. Because of insufficient
consideration of pathogenesis, risk-factor epidemiology
has sometimes been referred to as black-box epidemi-
ology (11). Biomarkers therefore fill a substantial need
in modern epidemiology (Fig. 2). Hulka and Wilcosky
(4) outlined the following purposes of using various
biomarkers: (a) elucidation of pathogenic mechanisms;
(b) improvement of etiologic classification of environ-
mentally related diseases; and (c) recognition of early
effects. In addition, some exposure biomarkers can be
applied in groups of exposed workers to assess the
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Black-box epidemiology
Biomarker epidemiology
Fig. 2. The “black box” often apparent in risk-factor epidemiology
may be effectively explored by the use of biomarkers as indicators
of pathogenetic steps.
extent of compliance with pollution abatement regula-
tions or effectiveness of preventive efforts in general.
Biomarkers can also be applied to document the com-
munity impact of an environmental hazard. In healthy
subjects, a biomarker may reflect individual hypersus-
ceptibility to specific chemical exposures and may
therefore serve as a basis for risk prediction. On an
individual basis, a biomarker may be used to support or
refute a diagnosis of a particular type of poisoning or
other chemically induced adverse effect. These applica-
tions clearly relate to central issues in environmental
epidemiology.
Conventional epidemiology has low sensitivity when
exposure is assessed indirectly, or when assessment of
the effects is based on crude indicators, such as diag-
noses from death certificates. Because of the poor
precision, misclassification is likely to occur, thus de-
creasing the sensitivity. Also, since major diseases take
years to develop, conventional epidemiology concerns
exposures of the past and may relate only partly to the
problems of exposures today. In addition, environmen-
tal health research has to confront the thorny question
of extrapolation from studies in experimental toxicol-
ogy. Biomarkers represent an important instrument to
tackle these problems.
Because biomarkers can be used in epidemiological
studies to classify and quantify environmental expo-
sures and related effects by methods that may even be
applicable in toxicological experiments, biomarker ep-
idemiology is currently undergoing rapid development
and expansion and is becoming one of the most prom-
ising areas of environmental research. Again, some
confusion has clouded the literature. Thus, papers on
genotoxicity biomarkers first used the term “mutation
epidemiology” (12), and subsequent publications usu-
ally referred to this area as “molecular epidemiology”
(7). The molecules referred to were generally markers
of genotoxic effects. Because genotoxicity could also be
reflected by changes in morphology (e.g., aneuploidy),
and because molecular biology methods may also be
applied for other types of biomarkers, a more appropri-
ate term for this field of research is obviously bio-
marker epidemiology.
Research Needs
Recent research has demonstrated the complexity of
some dose-response relations and the considerable
difficulty in identifying no-effect concentrations. For
example, for most organic compounds, quantitative
associations between exposures and the corresponding
adverse health effects are not yet available; in many
cases, even the primary target organs are not known
for sure. Biomarkers are likely to be of crucial value in
characterizing doses and effects in such studies. Ex-
trapolation from animal experiments is becoming a
sophisticated specialty within toxicology, and determi-
nation of comparable biomarkers in different species
may provide important evidence in this regard. How-
ever, evaluation of toxicity data and biomarker results
is often complicated by exposure to mixtures of sub-
stances, rather than exposure to a single compound at
a time.
As already indicated by the proceedings (1) of the
first Biomarker Conference in this series, multidisci-
plinary research is burgeoning and is likely to affect in
a profound way both environmental epidemiology and
toxicology, as well as preventive medicine. However,
biomarkers, new and old, must be evaluated carefully
with regard to their analytical, diagnostic, and etiologic
validity. Toxicokinetic aspects, effects of other factors,
and standardization of methodology must also be con-
sidered. These aspects have been clarified for only a
handful of biomarkers so far, and the need to obtain
such basic information is pressing. Schulte (13) re-
cently asserted that “application of these markers has
been less than optimum because of the failure of
investigators to be precise about the type of marker
that is needed or the specific purpose for which it is
used.” This criticism is somewhat harsh, but it does
reflect the fact that in the beginning of a new research
era insufficient attention is sometimes paid to charac-
terizing the study variables. Given the growth in bio-
marker research of high quality and relevance, future
research will hopefully remedy this problem.
Biomarker research at the author’s department is supported by
the Danish Medical Research Council.
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